Socal MP - Search Results

1

The price paradox of biosimilar-like long-acting insulin.

Mouslim MC, Rashidi ES, Levy JF, Socal MP, Trujillo AJ. Mouslim MC, et al. Among authors: socal mp. Am J Manag Care. 2022 Nov 1;28(11):e405-e410. doi: 10.37765/ajmc.2022.89265. Am J Manag Care. 2022. PMID: 36374658 Free article.

2

Medicaid spending and utilization of gene and RNA therapies for rare inherited conditions.

Odouard IC, Ballreich J, Socal MP. Odouard IC, et al. Among authors: socal mp. Health Aff Sch. 2024 Apr 26;2(5):qxae051. doi: 10.1093/haschl/qxae051. eCollection 2024 May. Health Aff Sch. 2024. PMID: 38770270 Free PMC article.

3

Spending on Dual Over-the-Counter and Prescription Drugs in the Medicare Part D Program.

Socal MP, Wang Y, Plummer E, Anderson GF, Bai G. Socal MP, et al. JAMA. 2024 Jan 2;331(1):72-75. doi: 10.1001/jama.2023.23126. JAMA. 2024. PMID: 38095888 Free PMC article.

4

Addressing the Drug-Shortage Crisis in Oncology.

Yang YT, Socal M, Bennett CL. Yang YT, et al. JAMA Oncol. 2024 Feb 1;10(2):155-156. doi: 10.1001/jamaoncol.2023.5722. JAMA Oncol. 2024. PMID: 38175651

5

Accelerated approval drug labels often lack information for clinical decision-making.

Ballreich J, Socal M, Bennett CL, Xuan A, Trujillo A, Anderson G. Ballreich J, et al. Pharmacotherapy. 2023 Apr;43(4):300-304. doi: 10.1002/phar.2789. Epub 2023 Mar 16. Pharmacotherapy. 2023. PMID: 36872463

6

Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates.

Costin J, Mouslim MC, Socal MP, Trujillo A. Costin J, et al. Among authors: socal mp. Pharmacoecon Open. 2024 Jan;8(1):115-118. doi: 10.1007/s41669-023-00447-6. Epub 2023 Nov 3. Pharmacoecon Open. 2024. PMID: 37921963 Free PMC article.

7

Dynamics of biological markets with multiple biosimilar competitors in the United States.

Mouslim MC, Socal MP, Trujillo AJ. Mouslim MC, et al. Among authors: socal mp. Expert Opin Biol Ther. 2024 Nov;24(11):1271-1278. doi: 10.1080/14712598.2024.2412648. Epub 2024 Oct 9. Expert Opin Biol Ther. 2024. PMID: 39378044

8

Strategic Manufacturer Response to the Medicaid Rebate Cap Removal.

Levy JF, Socal MP, Ballreich JM. Levy JF, et al. Among authors: socal mp. JAMA Health Forum. 2024 Nov 1;5(11):e243624. doi: 10.1001/jamahealthforum.2024.3624. JAMA Health Forum. 2024. PMID: 39546304 Free PMC article.

9

Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes.

Wang Y, Kang SY, Socal MP, Dusetzina SB. Wang Y, et al. Among authors: socal mp. J Manag Care Spec Pharm. 2024 Sep;30(9):903-907. doi: 10.18553/jmcp.2024.30.9.903. J Manag Care Spec Pharm. 2024. PMID: 39213140 Free PMC article.

10

Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs.

Anderson KE, DiStefano MJ, Liu A, Mattingly TJ 2nd, Socal MP, Anderson GF. Anderson KE, et al. Among authors: socal mp. Value Health. 2023 Sep;26(9):1381-1388. doi: 10.1016/j.jval.2023.05.018. Epub 2023 Jun 5. Value Health. 2023. PMID: 37285915 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters